Published Date: 23 Aug 2024
Patients with terminal illness explore end-of-life options
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]
Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.
Weight-Adjusted Waist Index Can Predict CVD Risk in Cardiovascular Kidney Metabolic Syndrome
1.
Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer
2.
An FDA panel supports the use of CAR T-cell therapy earlier in the treatment of multiple myeloma.
3.
In schizophrenia, sexual dysfunction is frequent.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
A video animation guide to assist young people who are fatigued from cancer.
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
ADCs and Bispecific Antibodies: Advancing the Future of Cancer Immunotherapy
3.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
4.
The Life-Saving Powers of Anemia: How to Combat the Disease.
5.
The Statistical Imperative: Navigating Trends, Precision, and Innovation in Gynecologic Oncology 2025
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VI
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation